% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Huber:281913,
      author       = {Huber, Hanna and Arranz, Javier and Arslan, Burak and
                      Leuzy, Antoine and Kittel, Oscar and di Molfetta, Guglielmo
                      and Benejam, Bessy and Videla, Laura and Barroeta, Isabel
                      and Soriano, Laura Del Hoyo and Maure-Blesa, Lucía and
                      Rodríguez-Baz, Íñigo and Arriola Infante, José Enrique
                      and Illán-Gala, Ignacio and Bejanin, Alexandre and
                      Montoliu-Gaya, Laia and Lleó, Alberto and Carmona-Iragui,
                      María and Alcolea, Daniel and Blennow, Kaj and Zetterberg,
                      Henrik and Fortea, Juan and Ashton, Nicholas J},
      title        = {{P}lasma p-tau217 as a biomarker of {A}lzheimer's disease
                      pathology in individuals with {D}own syndrome.},
      journal      = {Nature Communications},
      volume       = {16},
      number       = {1},
      issn         = {2041-1723},
      address      = {[London]},
      publisher    = {Springer Nature},
      reportid     = {DZNE-2025-01255},
      pages        = {9900},
      year         = {2025},
      abstract     = {Diagnosing Alzheimer's disease (AD) in adults with Down
                      syndrome (DS), a population with a high genetically
                      determined risk of AD, remains challenging. In this large
                      observational study including n = 2329 samples from the Down
                      Alzheimer Barcelona Neuroimaging Initiative (DABNI) and
                      euploid controls from the Sant Pau Initiative on
                      Neurodegeneration (SPIN) with and without symptomatic AD, we
                      investigate if the strong diagnostic performance of plasma
                      p-tau217 observed in sporadic AD extends to the DS
                      population. Plasma p-tau217 discriminated cognitively stable
                      individuals with DS from those with AD dementia with an AUC
                      of 0.96 $(95\%$ CI, 0.95-0.97), and from those with
                      prodromal AD with an AUC of 0.90 $(95\%$ CI, 0.87-0.92).
                      Amyloid β (Aβ) positive and Aβ negative individuals with
                      DS were distinguished with an AUC of 0.95 $(95\%$ CI,
                      0.92-0.99). In this study, we demonstrate that plasma
                      p-tau217 is highly accurate in detecting amyloid β
                      positivity and predicting clinical progression in
                      individuals with DS, outperforming other plasma biomarkers.
                      These findings support its use as a reliable, noninvasive
                      tool for early AD detection and management in individuals
                      with DS.},
      cin          = {AG Schneider},
      ddc          = {500},
      cid          = {I:(DE-2719)1011305},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41213934},
      doi          = {10.1038/s41467-025-65882-x},
      url          = {https://pub.dzne.de/record/281913},
}